Biohaven Pharmaceutical (NYSE:BHVN) announced its quarterly earnings results on Tuesday. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($1.20), Bloomberg Earnings reports.
NYSE BHVN opened at $29.95 on Thursday. Biohaven Pharmaceutical has a 12 month low of $29.11 and a 12 month high of $30.31.
Several research analysts have recently weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $36.00 price target on shares of Biohaven Pharmaceutical in a research report on Wednesday. Zacks Investment Research cut shares of Biohaven Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Wednesday. Canaccord Genuity set a $34.00 price target on shares of Biohaven Pharmaceutical and gave the company a “buy” rating in a research report on Friday, April 27th. Piper Jaffray reissued a “buy” rating on shares of Biohaven Pharmaceutical in a research report on Monday, March 26th. Finally, ValuEngine raised shares of Biohaven Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have assigned a buy rating to the stock. Biohaven Pharmaceutical presently has an average rating of “Hold” and a consensus price target of $37.14.
In other Biohaven Pharmaceutical news, VP Kimberly Gentile sold 5,000 shares of the company’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $32.87, for a total value of $164,350.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Robert Berman sold 35,000 shares of the company’s stock in a transaction dated Monday, March 12th. The shares were sold at an average price of $30.11, for a total transaction of $1,053,850.00. The disclosure for this sale can be found here. Insiders sold 113,038 shares of company stock worth $3,105,100 in the last ninety days. 34.20% of the stock is currently owned by corporate insiders.
About Biohaven Pharmaceutical
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops product candidates to treat neurological diseases, including rare disorders. Its lead product candidate is rimegepant, which is in Phase III clinical trials for the acute treatment of migraine. The company also develops trigriluzole, which is in a Phase II/III clinical trial used for the treatment of ataxias with an initial focus on spinocerebellar ataxia; and Phase II/III clinical trial for the treatment of obsessive compulsive disorders, as well as for the treatment of Alzheimer's diseases.
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.